Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

PURPOSE: We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)– amplified human xenografts in mice by inhibition of the HER2 pathway with lapatinib and trastuzumab to block all homo- and heterodimer signaling as well as by blockade of estrogen receptor (ER) when e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Rimawi, Mothaffar F., Mayer, Ingrid A., Forero, Andres, Nanda, Rita, Goetz, Matthew P., Rodriguez, Angel A., Pavlick, Anne C., Wang, Tao, Hilsenbeck, Susan G., Gutierrez, Carolina, Schiff, Rachel, Osborne, C. Kent, Chang, Jenny C.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2013
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3641695/
https://ncbi.nlm.nih.gov/pubmed/23569315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.44.8027
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars